HMB Cerebral Palsy Pilot Study
β-hydroxy-β-methylbutyrate (HMB) Pilot Feasibility and Efficacy Study in Cerebral Palsy (CP)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55101
- Gillette Children's Specialty Healthcare
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosed with cerebral palsy
- Spastic or mixed tone
- GMFCS Level I-III (i.e., ambulatory)
- 13-17 years old
- Physical training level expected to remain relatively constant over the study period
- Ability to follow directions, including swallowing multiple pills daily and complying with reproductive risk recommendations (post-menarchal females)
- Within reasonable driving distance to the University of Minnesota - Twin Cities
- Reads English
Exclusion Criteria:
- Pregnant, lactating, or trying to become pregnant
- Surgery in the past 9 months
- Botulinum toxin injections in past 3 months
- Selective dorsal rhizotomy in the past 12 months
- Upcoming invasive treatment within the study period that may affect strength or functional mobility (e.g., surgery, botulinum toxin injections, intrathecal baclofen pump or dosage change)
- Liver disease or liver disorder
- Kidney disease or disorder
- Prescription drug or nutrition supplement contraindications
- Excessive research or medical-related radiation exposure in the past 12 months (approximately 500 mrem or greater)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: HMB + Vitamin D3 Supplement
Supplement delivery will be a tablet containing both HMB & Vitamin D3.
HMB will be administered in its calcium salt form.
One tablet will contain 750 mg HMB + 250 IU of Vitamin D3.
The target dosage is 3 g HMB + 1000 IU of Vitamin D3 per day.
|
The supplement will be taken orally twice daily.
Participants will take 2 blended HMB + Vitamin D3 tablets in the morning and 2 tablets in the evening for 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in the incidence of Treatment-Emergent Adverse Events with supplementation as assessed by renal (kidney) function - specific gravity
Time Frame: Pre-supplementation (12 wks), post-supplementation (12 wks)
|
Specific gravity will be measured via urinalysis with microscopy (unitless; ratio of urine density [g/cm^3] divided by density of pure water).
|
Pre-supplementation (12 wks), post-supplementation (12 wks)
|
|
Difference in the incidence of Treatment-Emergent Adverse Events with supplementation as assessed by renal (kidney) function - pH
Time Frame: Pre-supplementation (12 wks), post-supplementation (12 wks)
|
pH will be measured via urinalysis with microscopy (usually presented unitless; moles H+ per liter).
|
Pre-supplementation (12 wks), post-supplementation (12 wks)
|
|
Difference in the incidence of Treatment-Emergent Adverse Events with supplementation as assessed by renal (kidney) function - BUN
Time Frame: Pre-supplementation (12 wks), post-supplementation (12 wks)
|
Blood urea nitrogen (BUN; units: mg/dL) will be measured using a blood sample.
|
Pre-supplementation (12 wks), post-supplementation (12 wks)
|
|
Difference in the incidence of Treatment-Emergent Adverse Events with supplementation as assessed by renal (kidney) function - creatinine
Time Frame: Pre-supplementation (12 wks), post-supplementation (12 wks)
|
Creatinine will be measured using a blood sample.
It will be used to estimate glomerular filtration rate (mL/min/m^2 body surface area).
|
Pre-supplementation (12 wks), post-supplementation (12 wks)
|
|
Difference in the incidence of Treatment-Emergent Adverse Events with supplementation as assessed by hepatic (liver) function - enzymes
Time Frame: Pre-supplementation (12 wks), post-supplementation (12 wks)
|
Hepatic enzyme function will be measured with a blood sample.
Outcomes include alkaline phosphatase [ALP], aspartate aminotransferase [AST], alanine aminotransferase [ALT] (all units: units per liter).
|
Pre-supplementation (12 wks), post-supplementation (12 wks)
|
|
Difference in the incidence of Treatment-Emergent Adverse Events with supplementation as assessed by hepatic (liver) function
Time Frame: Pre-supplementation (12 wks), post-supplementation (12 wks)
|
Hepatic function will be measured with a blood sample.
Outcomes of interest include bilirubin, albumin, and total protein (all units: g/dL).
|
Pre-supplementation (12 wks), post-supplementation (12 wks)
|
|
Difference in the incidence of Treatment-Emergent Adverse Events before and after supplementation as assessed by adverse events form
Time Frame: Pre-supplementation (12 wks), post-supplementation (12 wks)
|
Adverse events will be recorded using the NIH's Adverse Events Form, ver 2.
|
Pre-supplementation (12 wks), post-supplementation (12 wks)
|
|
Difference in the incidence of Treatment-Emergent Adverse Events before and after supplementation as assessed by checklist of changes to major organ systems
Time Frame: Pre-supplementation (12 wks), post-supplementation (12 wks)
|
Common complaints of major organ system experienced over the last 3 days will be self-reported as present or not present for: stomachache, nausea, dizziness, coughing, wheezing, chest pain, weakness, increased headache, negative mood, rash, dry scalp, dry skin, nail changes, ear pain, decreased memory, itching, swelling, diarrhea, stiff joints, nose bleeds, heart burn, numbness, nasal congestion, ringing in ears, increased stress, decreased libido, constipation, shortness of breath, loss of appetite, loss of energy, blood in urine, & blood in stool.
|
Pre-supplementation (12 wks), post-supplementation (12 wks)
|
|
Ability to comply with HMB supplementation as assessed by a daily diary & compliance check-ins
Time Frame: Post-supplementation (12 wks)
|
Participants will complete a daily paper or electronic diary to document taking their supplement.
Compliance checks will be conducted by the study staff via a call or email.
Unused supplements will be counted at the end of the study.
Compliance will be calculated as a percent (# of pills taken on time/total # of pills that should have been taken) x 100.
|
Post-supplementation (12 wks)
|
|
Ability to swallow HMB supplement as assessed by the PILL-5 survey
Time Frame: Week 1 of supplementation
|
The PILL-5 survey is a 5 question survey that measures physical (e.g., pill sticks in my throat) and emotional (e.g., I have a fear of swallowing pills) swallowing ability.
It will be self-reported using a 5-pt Likert scale (never, almost never, sometimes, almost always, always).
A total score is calculated (range 0-20, with 20 representing maximum pill dysphasia).
|
Week 1 of supplementation
|
|
Palatability of HMB supplement as assessed by the visual 5 faces hedonic scale
Time Frame: Week 1 of supplementation
|
Whether participants like or dislike the taste of the supplement will be measured with a 5 faces hedonic scale with the numerical anchors ranging from 1 to 5 (best) and text anchors: dislike a lot; dislike a little; neither like nor dislike; like a little; like a lot.
|
Week 1 of supplementation
|
|
Satisfaction of supplement dose volume as assessed by survey
Time Frame: Week 12 of supplementation
|
A question will measure if participants felt the dose volume (number of tablets) were acceptable (yes or no).
|
Week 12 of supplementation
|
|
Difference in satisfaction of supplement dose frequency as assessed by survey
Time Frame: Week 12 of supplementation
|
A question will measure if participants felt the frequency (2 times per day) was acceptable (yes or no).
|
Week 12 of supplementation
|
|
Difference in the incidence of Treatment-Emergent Adverse Events with supplementation as assessed by renal (kidney) function - microscopy
Time Frame: Pre-supplementation (12 wks), post-supplementation (12 wks)
|
Molecular concentrations in urine will be measured via urinalysis with microscopy.
The following molecular concentrations will be measured: total protein, glucose, ketones, blood, bilirubin, and urobilinogen (all units: unitless).
|
Pre-supplementation (12 wks), post-supplementation (12 wks)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in lower extremity strength with supplementation as assessed using a Biodex isokinetic system
Time Frame: Pre-supplementation (12 wks), post-supplementation (12 wks)
|
Isokinetic dynamometry will be used to measure peak torque of hip extensors & flexors, knee extensors & flexors, and ankle plantarflexors and dorsiflexors (Newton-meters/body mass).
|
Pre-supplementation (12 wks), post-supplementation (12 wks)
|
|
Change in muscle mass with supplementation as assessed by dual-energy x-ray absorptiometry (DXA)
Time Frame: Pre-supplementation (12 wks), post-supplementation (12 wks)
|
Skeletal muscle mass (kg) will be measured using a whole body DXA scan.
|
Pre-supplementation (12 wks), post-supplementation (12 wks)
|
|
Change in functional mobility with supplementation as assessed by the 10-meter walk test (10MWT)
Time Frame: Pre-supplementation (12 wks), post-supplementation (12 wks)
|
The 10MWT will be performed at the participant's fastest walking speed over a 14-m walkway, with 2-m on each end for acceleration and deceleration.
Time to travel the middle 10-m will be recorded by stopwatch and average speed (m/s) calculated.
Usual orthoses and assistive devices will be permitted and used at each repeat assessment.
|
Pre-supplementation (12 wks), post-supplementation (12 wks)
|
|
Change in functional mobility with supplementation as assessed by the Timed-up-and-go test (TUG)
Time Frame: Pre-supplementation (12 wks), post-supplementation (12 wks)
|
The TUG will be performed at self-selected speed using a standard height chair with arms.
Participants will stand up, walk 3-m, and return to their seat.
Time (seconds) will be measured.
Usual orthoses and assistive devices will be permitted and used at each repeat assessment.
|
Pre-supplementation (12 wks), post-supplementation (12 wks)
|
|
Change in functional mobility with supplementation as assessed by the 6 minute walk test (6MWT)
Time Frame: Pre-supplementation (12 wks), post-supplementation (12 wks)
|
The 6MWT will be performed at the participant's fastest walking speed on an indoor, oval walking path.
Distance travelled (m) will be recorded and average speed (m/s) calculated.
Usual orthoses and assistive devices will be permitted and used at each repeat assessment.
|
Pre-supplementation (12 wks), post-supplementation (12 wks)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY00015262
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.